Lucid Diagnostics
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
"This analytical validation study strongly complements EsoGuard's extensive peer-reviewed, published clinical validity and clinical utility evidence base," said Suman Verma, M.D., PhD, Chief Scientific Officer at Lucid Diagnostics. "The results demonstrate very robust analytical performance of the EsoGuard assay performed in our CLIA-certified, CAP-accredited, NY State-approved commercial laboratory."